Urinary Bladder Neoplasms
97
16
27
33
Key Insights
Highlights
Success Rate
69% trial completion
Published Results
23 trials with published results (24%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
15.5%
15 terminated out of 97 trials
68.8%
-17.8% vs benchmark
15%
15 trials in Phase 3/4
70%
23 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (97)
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer